We investigated the influence of CYP2D6 polymorphism on the pharmacokinetics of risperidone in Chinese patients with schizophrenia. The total number of north Han Chinese patients included in this study was 130, including 78 males and 52 females with schizophrenia aged 30.6 (18-46) years old, not known to be related to each other. Genotyping was performed using the iPLEX™ Assay with a Sequenom MassARRAY®-SNP platform (CapitalBio Technology Co., Ltd.). The polymorphisms detected were as follows: 1708delT, 886C>T, 1022C>T, 1847G>A, 2540delAACT, 100C>T, 1612T>A, 2989G>A, 77G>A, 3202C>T, 882G>C, 2951G>C, 1977_1978insG, 2550delAl, 1759G>A, 2616delAAG, 2936A>C, representing the following alleles: normal or uncertain function *1, *2,*43; decrease of function *9,*10, *14,*17, *41, *49; loss of function *3, *4, *6, *7, *11, *19, *20, *44, *56.
v. 4.14
